AstraZeneca partners with Oracle for AI-driven clinical trials

Oct 20 : AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve clinical research.• The collaboration will combine AstraZeneca’s drug develo


Business

AstraZeneca partners with Oracle for AI-driven clinical trials

AstraZeneca partners with Oracle for AI-driven clinical trials

FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo

Read a summary of this article on FAST.

Get bite-sized news via a new
cards interface. Give it a try.

Click here to return to FAST
Tap here to return to FAST

FAST

Oct 20 : AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve clinical research.

• The collaboration will combine AstraZeneca’s drug development expertise with Oracle’s AI and healthcare data capabilities to support patient matching and research

• Initial work will focus on cancer, cardiovascular, respiratory, immunology and rare diseases, and could also support earlier diagnosis of serious diseases

• The first project will support hypertension research in Abu Dhabi in partnership with UAE-based healthcare firm M42

Guess Word

Guess Word
Crack the word, one row at a time


Buzzword

Buzzword
Create words using the given letters


Mini Sudoku

Mini Sudoku
Tiny puzzle, mighty brain teaser


Mini Crossword

Mini Crossword
Small grid, big challenge


Word Search

Word Search
Spot as many words as you can


Show More


Show Less

• Patient recruitment remains one of the biggest challenges in clinical research, with delayed enrolment often extending trial timelines and increasing development costs

• Incorrect trial designs have also hurt AstraZeneca in the past, with delays on its breast cancer drug and nerve disorder treatment failure causing some worries

• AstraZeneca is seeking to expand its medicine portfolio as it targets over $80 billion in annual revenue by 2030, and works to address industry bottlenecks in drug development

Source: Reuters

Sign up for our newsletters

Get our pick of top stories and thought-provoking articles in your inbox

Inbox

Get the CNA app

Stay updated with notifications for breaking news and our best stories

Get WhatsApp alerts

Join our channel for the top reads for the day on your preferred chat app

Whatsapp

Get bite-sized news via a new
cards interface. Give it a try.

Click here to return to FAST
Tap here to return to FAST

FAST

Leave a Reply

Your email address will not be published. Required fields are marked *

About the Author

Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.

BlockSpare — News, Magazine and Blog Addons for (Gutenberg) Block Editor

Search the Archives

Access over the years of investigative journalism and breaking reports